| L Number | Hits | Search Text | DB | Time stamp |
|---|---|---|---|---|
| 1 | 0 | cell adj1 line near5 gene adj1 expression adj1 test adj1 compound | USPAT; US-PGPUB; DERWENT | 2003/03/18 10:45 |
| 3 | 4129 | cell adj1 line and gene adj1 expression and test adj1 compound | USPAT; US-PGPUB; DERWENT | 2003/03/18 10:46 |
| 2 | 7 | cell adj1 line and gene adj1 expression adj1 test adj1 compound | USPAT; US-PGPUB; DERWENT | 2003/03/18 10:47 |
| 4 | 2441 | (cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma | USPAT; US-PGPUB; DERWENT | 2003/03/18 10:48 |
| 5 | 0 | leukamia and ((cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma) | USPAT; US-PGPUB; DERWENT | 2003/03/18 10:48 |
| 6 | 389528 | ((cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma) and pattren or profile | USPAT; US-PGPUB; DERWENT | 2003/03/18 10:48 |
| 7 | 1590 | ((cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma) and (((cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma) and pattren or profile) | USPAT; US-PGPUB; DERWENT | 2003/03/18 10:49 |
| 8 | 1484 | (((cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma) and (((cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma) and pattren or profile)) and cell adj1 type | USPAT; US-PGPUB; DERWENT | 2003/03/18 10:49 |
| 9 | 917 | ((((cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma) and (((cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma) and pattren or profile)) and cell adj1 type) and alteration | USPAT; US-PGPUB; DERWENT | 2003/03/18 10:52 |
| 10 | 917 | (((((cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma) and (((cell adj1 line and gene adj1 expression and test adj1 compound) and sarcoma) and pattren or profile)) and cell adj1 type) and alteration) and function | USPAT; US-PGPUB; DERWENT | 2003/03/18 10:56 |

NCBI PubMed National Library of Medicine NLM

PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search PubMed for gene expression in different cells and functi Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 20 Sort Send to Text

Items 1-15 of 15 One page.

Entrez PubMed

PubMed Services

Related Resources

1: Minier C, Lelong C, Djemel N, Rodet F, Tutundjian R, Favrel P, Mathieu M, Leboulenger F. Related Articles, Links

Expression and activity of a multixenobiotic resistance system in the Pacific oyster Crassostrea gigas.
Mar Environ Res. 2002 Sep-Dec;54(3-5):455-9.
PMID: 12408601 [PubMed - indexed for MEDLINE]

2: Schwartz IF, Hershkovitz R, Iaina A, Gnessin E, Wollman Y, Chernichowski T, Blum M, Levo Y, Schwartz D. Related Articles, Links

Garlic attenuates nitric oxide production in rat cardiac myocytes through inhibition of inducible nitric oxide synthase and the arginine transporter CAT-2 (cationic amino acid transporter-2).
Clin Sci (Lond). 2002 May;102(5):487-93.
PMID: 11980565 [PubMed - indexed for MEDLINE]

3: Vogensen SB, Jensen HS, Stensbol TB, Frydenvang K, Bang-Andersen B, Johansen TN, Egebjerg J, Krogsgaard-Larsen P. Related Articles, Links

Resolution, configurational assignment, and enantiopharmacology of 2-amino-3-[3-hydroxy-5-(2-methyl-2H- tetrazol-5-yl)isoxazol-4-yl]propionic acid, a potent GluR3- and GluR4-preferring AMPA receptor agonist.
Chirality. 2000 Nov;12(10):705-13.
PMID: 11054828 [PubMed - indexed for MEDLINE]

4: Wang Y, Ye J, Ganapathy V, Longo N. Related Articles, Links

Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency.
Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2356-60.
PMID: 10051646 [PubMed - indexed for MEDLINE]

5: Katiyar SK, Korman NJ, Mukhtar H, Agarwal R. Related Articles, Links

Protective effects of silymarin against photocarcinogenesis in a mouse skin model.
J Natl Cancer Inst. 1997 Apr 16;89(8):556-66.
PMID: 9106644 [PubMed - indexed for MEDLINE]

6: Mehta RG, Moriarty RM, Mehta RR, Penmasta R, Lazzaro G, Constantinou A, Guo L. Related Articles, Links

Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5.
J Natl Cancer Inst. 1997 Feb 5;89(3):212-8.
PMID: 9017001 [PubMed - indexed for MEDLINE]

☐7: Brem AS, Bina RB, Klinger JR, King T, Werner JC. Related Articles, Links

Glucocorticoid metabolism in the newborn rat heart.
Proc Soc Exp Biol Med. 1995 Jun;209(2):146-51.
PMID: 7770464 [PubMed - indexed for MEDLINE]

☐8: Broughton BC, Steingrimsdottir H, Weber CA, Lehmann AR. Related Articles, Links

Mutations in the xeroderma pigmentosum group D DNA repair/transcription gene in patients with trichothiodystrophy.
Nat Genet. 1994 Jun;7(2):189-94.
PMID: 7920640 [PubMed - indexed for MEDLINE]

☐9: Brigle KE, Spinella MJ, Westin EH, Goldman ID. Related Articles, Links

Increased expression and characterization of two distinct folate binding proteins in murine erythroleukemia cells.
Biochem Pharmacol. 1994 Jan 20;47(2):337-45.
PMID: 8304978 [PubMed - indexed for MEDLINE]

☐10: Torma H, Asselineau D, Andersson E, Martin B, Reiniche P, Chambon P, Shroot B, Darmon M, Vahlquist A. Related Articles, Links

Biologic activities of retinoic acid and 3,4-didehydroretinoic acid in human keratinocytes are similar and correlate with receptor affinities and transactivation properties.
J Invest Dermatol. 1994 Jan;102(1):49-54.
PMID: 7507153 [PubMed - indexed for MEDLINE]

☐11: Beck CA, Weigel NL, Edwards DP. Related Articles, Links

Effects of hormone and cellular modulators of protein phosphorylation on transcriptional activity, DNA binding, and phosphorylation of human progesterone receptors.
Mol Endocrinol. 1992 Apr;6(4):607-20.
PMID: 1316549 [PubMed - indexed for MEDLINE]

☐12: Shimada T, Guengerich FP. Related Articles, Links

Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver.
Proc Natl Acad Sci U S A. 1989 Jan;86(2):462-5.
PMID: 2492107 [PubMed - indexed for MEDLINE]

☐13: Yelton MM, Hamer JE, de Souza ER, Mullaney EJ, Timberlake WE. Related Articles, Links

Developmental regulation of the Aspergillus nidulans trpC gene.
Proc Natl Acad Sci U S A. 1983 Dec;80(24):7576-80.
PMID: 6324178 [PubMed - indexed for MEDLINE]

☐14: Fahmy MJ, Fahmy OG. Related Articles, Links

Misregulation versus mutation in the alteration of gene expression by carcinogens through interactions with transposable elements in Drosophila melanogaster.
Teratog Carcinog Mutagen. 1983;3(1):27-39.
PMID: 6132455 [PubMed - indexed for MEDLINE]

☐ 15: Hoffman-Liebermann B, Liebermann D, Sachs L. Related Articles, Links

Regulation of gene expression by tumor promoters. III. Complementation of the developmental program in myeloid leukemic cells by regulating mRNA production and mRNA translation.

Int J Cancer. 1981 Nov 15;28(5):615-20.

PMID: 6975761 [PubMed - indexed for MEDLINE]

Display Summary Show: 20 Sort Send to Text

Items 1-15 of 15 One page.

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Freedom of Information Act | Disclaimer

Mar 6 2003 10:50:17

Welcome to STN International! Enter x:x

LOGINID:ssspta1656sxc

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27 Oct 21 EVENTLINE has been reloaded
NEWS 28 Oct 24 BEILSTEIN adds new search fields
NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002
NEWS 31 Nov 18 DKILIT has been renamed APOLLIT
NEWS 32 Nov 25 More calculated properties added to REGISTRY
NEWS 33 Dec 02 TIBKAT will be removed from STN
NEWS 34 Dec 04 CSA files on STN
NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36 Dec 17 TOXCENTER enhanced with additional content
NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN
NEWS 38 Dec 30 ISMEC no longer available
NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 40 Jan 21 NUTRACEUT offering one free connect hour in February 2003
NEWS 41 Jan 21 PHARMAML offering one free connect hour in February 2003
NEWS 42 Jan 29 Simultaneous left and right truncation added to COMPENDEX,

```
                  ENERGY, INSPEC
 NEWS 43  Feb 13  CANCERLIT is no longer being updated
 NEWS 44  Feb 24  METADEX enhancements
 NEWS 45  Feb 24  PCTGEN now available on STN
 NEWS 46  Feb 24  TEMA now available on STN
 NEWS 47  Feb 26  NTIS now allows simultaneous left and right truncation
 NEWS 48  Feb 26  PCTFULL now contains images
 NEWS 49  Mar 04  SDI PACKAGE for monthly delivery of multifile SDI results

 NEWS EXPRESS  January 6 CURRENT WINDOWS VERSION IS V6.01a,
               CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 11:40:02 ON 18 MAR 2003

=> FIL BIOSIS MEDLINE EMBASE LIFESCI CAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'BIOSIS' ENTERED AT 11:40:39 ON 18 MAR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 11:40:39 ON 18 MAR 2003

FILE 'EMBASE' ENTERED AT 11:40:39 ON 18 MAR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

FILE 'LIFESCI' ENTERED AT 11:40:39 ON 18 MAR 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)


FILE 'CAPLUS' ENTERED AT 11:40:39 ON 18 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s gene (w) expression (2a) test (w) compound
   3 FILES SEARCHED...
L1             8 GENE (W) EXPRESSION (2A) TEST (W) COMPOUND
```

```
=> dup remove l1
PROCESSING COMPLETED FOR L1
L2             7 DUP REMOVE L1 (1 DUPLICATE REMOVED)

=> d l2 1-7

L2   ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2003 ACS
AN   2003:173780  CAPLUS
TI   Bioassay for screening toxins using Saccharomyces cerevisiae reporter
gene
     expression system linked to toxin-induced gene promoter
IN   Iwahashi, Hitoshi; Momose, Yuko; Kitagawa, Emiko; Takahashi, Junko
PA   National Institute of Advanced Industrial Science and Technology, Japan;
     Daikin Industries, Ltd.
SO   PCT Int. Appl., 150 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.  DATE
     ---------------    ----  --------       ---------------  --------
PI   WO 2003018792      A1    20030306       WO 2002-JP8495   20020823
         W:  JP, US
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT,
             LU, MC, NL, PT, SE, SK, TR
PRAI JP 2001-255379     A     20010824

L2   ANSWER 2 OF 7  CAPLUS  COPYRIGHT 2003 ACS
AN   2003:29507  CAPLUS
DN   138:84442
TI   Screening regulators of visceral fat accumulation by microarray gene
     expression profile analysis
IN   Matsuki, Yasushi; Iguchi, Haruhisa
PA   Sumitomo Chemical Co., Ltd., Japan
SO   Jpn. Kokai Tokkyo Koho, 34 pp.
     CODEN: JKXXAF
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.  DATE
     ---------------    ----  --------       ---------------  --------
PI   JP 2003009900      A2    20030114       JP 2001-198641   20010629
PRAI JP 2001-198641           20010629

L2   ANSWER 3 OF 7  CAPLUS  COPYRIGHT 2003 ACS
AN   2002:906464  CAPLUS
DN   138:1266
TI   Molecular toxicology modeling by gene expression profiling in the
presence
     of renal toxicity markers
IN   Mendrick, Donna; Porter, Mark; Johnson, Kory; Higgs, Brandon; Castle,
     Arthur; Elashoff, Michael
PA   Gene Logic, Inc., USA
SO   PCT Int. Appl., 446 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.  DATE
     ---------------    ----  --------       ---------------  --------
```

PI WO 2002095000 A2 20021128 WO 2002-US16173 20020522
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI US 2001-292335P P 20010522
US 2001-297523P P 20010613
US 2001-298925P P 20010619
US 2001-303807P P 20010710
US 2001-303808P P 20010710
US 2001-303810P P 20010710
US 2001-315047P P 20010828
US 2001-324928P P 20010927
US 2001-330462P P 20011022
US 2001-330867P P 20011101
US 2001-331805P P 20011121
US 2001-336144P P 20011206
US 2001-340873P P 20011219
US 2002-357842P P 20020221
US 2002-357843P P 20020221
US 2002-357844P P 20020221
US 2002-364134P P 20020315
US 2002-370144P P 20020408
US 2002-370206P P 20020408
US 2002-370247P P 20020408
US 2002-372794P P 20020417
US 2002-371679P P 20020421

L2 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS
AN 2002:107604 CAPLUS
DN 136:146134
TI Molecular toxicology modeling based on global changes in gene expression profiles and expressed nucleic acid markers for drug toxicity
IN Mendrick, Donna; Porter, Mark W.; Johnson, Kory R.; Castle, Arthur L.; Elashoff, Michael R.
PA Gene Logic, Inc., USA
SO PCT Int. Appl., 239 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2002010453 | A2 | 20020207 | WO 2001-US23872 | 20010730 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| US 2002119462 | A1 | 20020829 | US 2001-917800 | 20010731 |

PRAI US 2000-222040P P 20000731
US 2000-244880P P 20001102
US 2001-290029P P 20010511
US 2001-290645P P 20010515
US 2001-292336P P 20010522
US 2001-295798P P 20010606
US 2001-297457P P 20010613
US 2001-298884P P 20010619
US 2001-303459P P 20010709

L2 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 1
AN 2002:125899 CAPLUS
DN 136:351414
TI Human genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
IN Lillie, James; Xu, Yongyao; Wang, Youzhen; Steinmann, Kathleen
PA Millennium Predictive Medicine, Inc., USA
SO PCT Int. Appl., 3695 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2001051628 | A2 | 20010719 | WO 2001-XB798 | 20010110 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| WO 2001051628 | A2 | 20010719 | WO 2001-US798 | 20010110 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |

PRAI US 2000-176077P P 20000114
US 2000-189167P P 20000314
US 2000-192099P P 20000324
US 2000-193480P P 20000329
US 2000-205230P P 20000515
US 2000-211315P P 20000609
US 2000-220534P P 20000725
WO 2001-US798 W 20010110

L2 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS
AN 1999:640973 CAPLUS
DN 131:253332
TI Method for detecting change in **gene expression** induced by **test compounds**
IN Muramatsu, Masaaki; Wakao, Hiroshi; Wakao, Rika; Yano, Kazuhiro; Noguchi, Teruhisa; Suyama, Akira

```
PA   Helix Research Institute, Japan
SO   PCT Int. Appl., 26 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.   DATE
     ---------------   ----  --------       ---------------   --------
PI   WO 9950401         A1   19991007       WO 1999-JP1574    19990326
         W:  CA, JP, US
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE
PRAI JP 1998-100096          19980327
RE.CNT  8     THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2   ANSWER 7 OF 7  CAPLUS  COPYRIGHT 2003 ACS
AN   1992:248406  CAPLUS
DN   116:248406
TI   Screening assays for inhibitors of oncoprotein action
IN   Brent, Roger; Golemis, Erica; Lech, Karen F.; Anderson, Catherine
PA   USA
SO   PCT Int. Appl., 48 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.        KIND  DATE           APPLICATION NO.   DATE
     ---------------   ----  --------       ---------------   --------
PI   WO 9205286         A1   19920402       WO 1991-US6839    19910920
         W:  AU, CA, CS, FI, HU, JP, KR, NO, SU, US
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE
     AU 9186272         A1   19920415       AU 1991-86272     19910920
     EP 550592          A1   19930714       EP 1991-917394    19910920
     EP 550592          B1   19970115
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE
     JP 06503713        T2   19940428       JP 1991-516071    19910920
     HU 66827           A2   19950130       HU 1993-822       19910920
     AT 147793          E    19970215       AT 1991-917394    19910920
     CN 1065092         A    19921007       CN 1991-110638    19910921
     ZA 9107616         A    19930924       ZA 1991-7616      19910924
     NO 9301061         A    19930521       NO 1993-1061      19930323
     US 5580721         A    19961203       US 1993-50198     19931007
PRAI US 1990-586781          19900924
     WO 1991-US6839          19910920


=> s gene (w) expression and cell (w) types
   3 FILES SEARCHED...
L3       20464 GENE (W) EXPRESSION AND CELL (W) TYPES

=> s l3 and test (w) compound
L4            5 L3 AND TEST (W) COMPOUND

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5            3 DUP REM L4 (2 DUPLICATES REMOVED)

=> d l5 1-3
```

L5 ANSWER 1 OF 3 MEDLINE
AN 2002352270 MEDLINE
DN 22090062 PubMed ID: 12096331
TI [Improving the embryonic stem cell test (EST) by establishing molecular endpoints of tissue specific development using murine embryonic stem cells (D3 cells)].
Etablierung molekularer Endpunkte zur Weiterentwicklung des Embryonalen Stammzelltests (EST) mit embryonalen Stammzellen der Maus (Zelllinie D3).
AU Seiler Andrea; Visan Anke; Pohl Ingeborg; Genschow Elke; Buesen Roland; Spielmann Horst
CS Zentralstelle zur Erfassung und Bewertung von Ersatz- und Erganzungsmethoden zum Tierversuch (ZEBET), Bundesinstitut fur gesundheitlichen Verbraucherschutz und Veterinarmedizin (BgVV), D-Berlin, Germany.. seiler.zebet@bgvv.de
SO ALTEX, (2002) 19 Suppl 1 55-63.
Journal code: 100953980. ISSN: 0946-7785.
CY Germany: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA German
FS Priority Journals
EM 200210
ED Entered STN: 20020704
Last Updated on STN: 20021008
Entered Medline: 20021004

L5 ANSWER 2 OF 3 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 1
AN 2001:501809 BIOSIS
DN PREV200100501809
TI Molecular markers in embryonic stem cells.
AU zur Nieden, N. I. (1); Ruf, L. J.; Kempka, G.; Hildebrand, H.; Ahr, H. J.
CS (1) Research Toxicology, Bayer AG, 42096, Wuppertal: nicole.melzer.nm.@bayer.ag.de Germany
SO Toxicology In Vitro, (August October, 2001) Vol. 15, No. 4-5, pp. 455-461.
print.
ISSN: 0887-2333.
DT Article
LA English
SL English

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 1999:487431 CAPLUS
DN 131:112381
TI **Gene expression** fingerprint and use in compound screening for developing therapeutics
IN Johnson, Paul H.; Ponte, Phyllis A.; Zajchowski, Deborah A.
PA Schering Aktiengesellschaft, Germany
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 9937817 | A1 | 19990729 | WO 1999-US1552 | 19990125 |

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,

```
            KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
            MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
            TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,
            TJ, TM
        RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
            FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
            CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    CA 2317650        AA   19990729       CA 1999-2317650  19990125
    AU 9923419        A1   19990809       AU 1999-23419    19990125
    EP 1051516        A1   20001115       EP 1999-903380   19990125
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
    JP 2002505852     T2   20020226       JP 2000-528723   19990125
PRAI US 1998-13496    A2   19980126
    US 1999-236026    A    19990122
    WO 1999-US1552    W    19990125
RE.CNT  2     THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d his

     (FILE 'HOME' ENTERED AT 11:40:02 ON 18 MAR 2003)

     FILE 'BIOSIS, MEDLINE, EMBASE, LIFESCI, CAPLUS' ENTERED AT 11:40:39 ON
18
     MAR 2003
L1             8 S GENE (W) EXPRESSION (2A) TEST (W) COMPOUND
L2             7 DUP REMOVE L1 (1 DUPLICATE REMOVED)
L3         20464 S GENE (W) EXPRESSION AND CELL (W) TYPES
L4             5 S L3 AND TEST (W) COMPOUND
L5             3 DUP REM L4 (2 DUPLICATES REMOVED)

=> medline
MEDLINE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> FIL MEDLINE
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                34.88      35.09

FILE 'MEDLINE' ENTERED AT 11:48:11 ON 18 MAR 2003

 FILE LAST UPDATED: 16 MAR 2003 (20030316/UP).  FILE COVERS 1958 TO DATE.

 On June 9, 2002, MEDLINE was reloaded.  See HELP RLOAD for details.

 MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
 MeSH 2003 vocabulary.  See http://www.nlm.nih.gov/mesh/summ2003.html
 for a description on changes.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> E POWELL THOMAS/AU 25
E1             1     POWELL TAYLOR D/AU
E2             1     POWELL THERESA L/AU
```

```
E3            0 --> POWELL THOMAS/AU
E4            2     POWELL THOMAS A/AU
E5            2     POWELL THREETS K/AU
E6            3     POWELL TIA/AU
E7            1     POWELL TIM/AU
E8            1     POWELL TIM D/AU
E9            3     POWELL TOM/AU
E10          59     POWELL TUCK J/AU
E11          16     POWELL V/AU
E12           1     POWELL V D JR/AU
E13           2     POWELL V I/AU
E14           1     POWELL V JR/AU
E15           2     POWELL V L/AU
E16           1     POWELL V R/AU
E17           1     POWELL VINDEN B/AU
E18           1     POWELL VIVIEN I/AU
E19          60     POWELL W/AU
E20          13     POWELL W A/AU
E21           1     POWELL W A JR/AU
E22           1     POWELL W B/AU
E23          14     POWELL W C/AU
E24           6     POWELL W D/AU
E25           4     POWELL W E/AU

=> E POWELL T/AU 25
E1            1     POWELL SUZANNE K/AU
E2            1     POWELL SUZANNE Z/AU
E3          141 --> POWELL T/AU
E4            8     POWELL T A/AU
E5            4     POWELL T E/AU
E6            1     POWELL T E 3RD/AU
E7            4     POWELL T F/AU
E8           14     POWELL T G/AU
E9            5     POWELL T H/AU
E10          33     POWELL T J/AU
E11           7     POWELL T J JR/AU
E12          28     POWELL T L/AU
E13           2     POWELL T M/AU
E14           8     POWELL T O/AU
E15         172     POWELL T P/AU
E16           1     POWELL T R/AU
E17           1     POWELL T S/AU
E18           5     POWELL T V/AU
E19          17     POWELL T W/AU
E20           1     POWELL T W JR/AU
E21           1     POWELL T W SR/AU
E22           1     POWELL TAMMY P/AU
E23           1     POWELL TAYLOR D/AU
E24           1     POWELL THERESA L/AU
E25           2     POWELL THOMAS A/AU

=> E 25
E26           2     POWELL THREETS K/AU
E27           3     POWELL TIA/AU
E28           1     POWELL TIM/AU
E29           1     POWELL TIM D/AU
E30           3     POWELL TOM/AU
E31          59     POWELL TUCK J/AU
E32          16     POWELL V/AU
E33           1     POWELL V D JR/AU
```

```
E34          2     POWELL V I/AU
E35          1     POWELL V JR/AU
E36          2     POWELL V L/AU
E37          1     POWELL V R/AU
E38          1     POWELL VINDEN B/AU
E39          1     POWELL VIVIEN I/AU
E40         60     POWELL W/AU
E41         13     POWELL W A/AU
E42          1     POWELL W A JR/AU
E43          1     POWELL W B/AU
E44         14     POWELL W C/AU
E45          6     POWELL W D/AU
E46          4     POWELL W E/AU
E47         16     POWELL W F/AU
E48          7     POWELL W H/AU
E49         16     POWELL W J/AU
E50         79     POWELL W J JR/AU

=> S (E10) AND 1990<=PY<=2000
            33 "POWELL T J"/AU
       4625401 1990<=PY<=2000
L6          17 ("POWELL T J"/AU) AND 1990<=PY<=2000

=> DIS L6 1- TI
YOU HAVE REQUESTED DATA FROM 17 ANSWERS - CONTINUE? Y/(N):Y

L6   ANSWER 1 OF 17     MEDLINE
TI   Chronic neurobehavioural effects of mercury poisoning on a group of Zulu
     chemical workers.

L6   ANSWER 2 OF 17     MEDLINE
TI   Psychiatrists' referrals to self-help groups for people with mood
     disorders.

L6   ANSWER 3 OF 17     MEDLINE
TI   A discrete subpopulation of dendritic cells transports apoptotic
     intestinal epithelial cells to T cell areas of mesenteric lymph nodes.

L6   ANSWER 4 OF 17     MEDLINE
TI   Derivation of temporary emergency exposure limits (TEELs).

L6   ANSWER 5 OF 17     MEDLINE
TI   Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine
     kinase inhibitors.

L6   ANSWER 6 OF 17     MEDLINE
TI   Recommended default methodology for analysis of airborne exposures to
     mixtures of chemicals in emergencies.

L6   ANSWER 7 OF 17     MEDLINE
TI   Attitudes of AA contact persons toward group participation by persons
with
     a mental illness.

L6   ANSWER 8 OF 17     MEDLINE
TI   Inhibition of platelet-derived growth factor-mediated signal transduction
     and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-
     carboxamide.

L6   ANSWER 9 OF 17     MEDLINE
```

TI SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

L6 ANSWER 10 OF 17 MEDLINE
TI A follow-up study of patients hospitalized after minor head injury.

L6 ANSWER 11 OF 17 MEDLINE
TI A tumor-derived protein which provides T-cell costimulation through accessory cell activation.

L6 ANSWER 12 OF 17 MEDLINE
TI Ontogeny of tolerogen-responsive lymphocytes following neonatal inoculation of class II disparate semiallogeneic cells.

L6 ANSWER 13 OF 17 MEDLINE
TI The secreted tumor-associated antigen 90K is a potent immune stimulator.

L6 ANSWER 14 OF 17 MEDLINE
TI Self-help research and the public mental health system.

L6 ANSWER 15 OF 17 MEDLINE
TI In vitro suppression of cytotoxic T cell generation by lymphocytes from mice rendered neonatally tolerant of class II MHC alloantigens.

L6 ANSWER 16 OF 17 MEDLINE
TI Influence of I-E expression on induction of neonatal transplantation tolerance.

L6 ANSWER 17 OF 17 MEDLINE
TI I-E molecules and I-E-reactive T cells play a central role in neonatal H-2
tolerance.

=> DIS L6 1-10 IBIB ABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.10 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L6 ANSWER 1 OF 17 MEDLINE
ACCESSION NUMBER: 2000478714 MEDLINE
DOCUMENT NUMBER: 20483371 PubMed ID: 11030454
TITLE: Chronic neurobehavioural effects of mercury poisoning on a group of Zulu chemical workers.
AUTHOR: **Powell T J**
CORPORATE SOURCE: West Berkshire Priority Care Services, NHS Trust, Reading, UK.. trevorp@wbpcs-tr.anglox.nhs.uk
SOURCE: BRAIN INJURY, **(2000 Sep)** 14 (9) 797-814.
Journal code: 8710358. ISSN: 0269-9052.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200102
ENTRY DATE: Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20010215
AB PRIMARY OBJECTIVE: To assess the nature and severity of reported neurobehavioural symptoms of mercury poisoning, in a group of Zulu chemical workers (n = 16), employed by a mercury processing plant, exposed

to neurotoxic levels of mercury, 5 years after exposure. RESEARCH DESIGN: A group-control design was adopted, where the exposed group was matched for age, sex, race, occupational and educational background. METHOD/PROCEDURES: Both groups were administered a specially selected battery of psychometric tests to measure neuropsychological functioning. OUTCOME AND RESULTS: The exposed group had significantly impaired short term verbal and spatial memory, impaired sustained and divided attention, and impaired motor speed. They also suffered from elevated clinical levels of psychiatric symptomatology, including anxiety, depression and phobic avoidance, and neurological symptoms of tremor, weakness in the limbs, and excessive sweating. CONCLUSIONS: The exposed group suffered from varying degrees of permanent neuropsychological disability, which adversely affects their ability to work and be financially independent. Psychometric measures for monitoring cognitive symptoms are discussed.

L6 ANSWER 2 OF 17 MEDLINE
ACCESSION NUMBER: 2000392640 MEDLINE
DOCUMENT NUMBER: 20287784 PubMed ID: 10828116
TITLE: Psychiatrists' referrals to self-help groups for people with mood disorders.
AUTHOR: **Powell T J**; Silk K R; Albeck J H
CORPORATE SOURCE: School of Social Work, University of Michigan, Ann Arbor, MI 48109-1106, USA.. tpowell@umich.edu
CONTRACT NUMBER: MH46399 (NIMH)
SOURCE: PSYCHIATRIC SERVICES, **(2000 Jun)** 51 (6) 809-11. Journal code: 9502838. ISSN: 1075-2730.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200008
ENTRY DATE: Entered STN: 20000824
Last Updated on STN: 20000824
Entered Medline: 20000817
AB The study examined psychiatrists' referrals to and support for participation in self-help groups by people with mood disorders. Massachusetts and Michigan psychiatrists with a special interest in patients with mood disorders were surveyed; the 278 respondents represented a 78 percent response rate. About three-fourths of the psychiatrists reported that they made referrals to and felt knowledgeable about self-help groups. However, less than half had self-help literature available or discussed self-help groups with their patients. Beliefs that a patient would gain a better understanding of the illness and would receive support after an episode of illness were positively related to support for self-help. Beliefs that the program was inappropriate and that it lacked professional oversight were negatively related.

L6 ANSWER 3 OF 17 MEDLINE
ACCESSION NUMBER: 2000130287 MEDLINE
DOCUMENT NUMBER: 20130287 PubMed ID: 10662789
TITLE: A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes.
COMMENT: Comment in: J Exp Med. 2000 Feb 7;191(3):411-6
AUTHOR: Huang F P; Platt N; Wykes M; Major J R; **Powell T J**; Jenkins C D; MacPherson G G

CORPORATE SOURCE: Sir William Dunn School of Pathology, University of Oxford,
Oxford OX1 3RE, United Kingdom.
SOURCE: JOURNAL OF EXPERIMENTAL MEDICINE, **(2000 Feb 7)** 191 (3) 435-44.
Journal code: 2985109R. ISSN: 0022-1007.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200004
ENTRY DATE: Entered STN: 20000427
Last Updated on STN: 20021231
Entered Medline: 20000418

AB This study identifies a dendritic cell (DC) subset that constitutively transports apoptotic intestinal epithelial cell remnants to T cell areas of mesenteric lymph nodes in vivo. Rat intestinal lymph contains two DC populations. Both populations have typical DC morphology, are major histocompatibility complex class II(hi), and express OX62, CD11c, and B7. CD4(+)/OX41(+) DCs are strong antigen-presenting cells (APCs). CD4(-)/OX41(-) DCs are weak APCs and contain cytoplasmic apoptotic DNA, epithelial cell-restricted cytokeratins, and nonspecific esterase (NSE)(+) inclusions, not seen in OX41(+) DCs. Identical patterns of NSE electrophoretic variants exist in CD4(-)/OX41(-) DCs, intestinal epithelial cells, and mesenteric node DCs but not in other DC populations, macrophages, or tissues. Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling (TUNEL)-positive DCs and strongly NSE(+) DCs are present in intestinal lamina propria. Peyer's patches and mesenteric but not other lymph nodes contain many strongly NSE(+) DCs in interfollicular and T cell areas. Similar DCs are seen in the ileum and in T cell areas of mesenteric nodes in gnotobiotic rats. These results show that a distinct DC subset constitutively endocytoses and transports apoptotic cells to T cell areas and suggest a role for these DCs in inducing and maintaining peripheral self-tolerance.

L6 ANSWER 4 OF 17 MEDLINE
ACCESSION NUMBER: 2000108988 MEDLINE
DOCUMENT NUMBER: 20108988 PubMed ID: 10641012
TITLE: Derivation of temporary emergency exposure limits (TEELs).
AUTHOR: Craig D K; Davis J S; Hansen D J; Petrocchi A J; **Powell T J**; Tuccinardi T E Jr
CORPORATE SOURCE: Westinghouse Safety Management Solutions, Inc., Aiken, SC 29803, USA.
SOURCE: JOURNAL OF APPLIED TOXICOLOGY, **(2000 Jan-Feb)** 20 (1) 11-20.
Journal code: 8109495. ISSN: 0260-437X.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200003
ENTRY DATE: Entered STN: 20000407
Last Updated on STN: 20000407
Entered Medline: 20000324

AB Short-term chemical concentration limits are used in a variety of

applications, including emergency planning and response, hazard assessment and safety analysis. Development of emergency response planning guidelines (ERPGs) and acute exposure guidance levels (AEGLs) are predicated on this need. Unfortunately, the development of peer-reviewed community exposure limits for emergency planning cannot be done rapidly (relatively few ERPGs or AEGLs are published each year). To be protective of Department of Energy (DOE) workers, on-site personnel and the adjacent general public, the DOE Subcommittee on Consequence Assessment and Protective Actions (SCAPA) has developed a methodology for deriving temporary emergency exposure limits (TEELs) to serve as temporary guidance until ERPGs or AEGLs can be developed. These TEELs are approximations to ERPGs to be used until peer-reviewed toxicology-based ERPGs, AEGL or equivalents can be developed. Originally, the TEEL method used only hierarchies of published concentration limits (e.g. PEL- or TLV-TWAs, -STELs or -Cs, and IDLHs) to provide estimated values approximating ERPGs. Published toxicity data (e.g. lc(50), lc(LO), ld(50) and ld(LO) for TEEL-3, and tc(LO) and td(LO) for TEEL-2) are included in the expanded method for deriving TEELs presented in this paper. The addition here of published toxicity data (in addition to the exposure limit hierarchy) enables TEELs to be developed for a much wider range of chemicals than before. Hierarchy-based values take precedence over toxicity-based values, and human toxicity data are used in preference to animal toxicity data. Subsequently, default assumptions based on statistical correlations of ERPGs at different levels (e.g. ratios of ERPG-3s to ERPG-2s) are used to calculate TEELs where there are gaps in the data. Most required input data are available in the literature and on CD ROMs, so the required TEELs for a new chemical can be developed quickly. The new TEEL hierarchy/toxicity methodology has been used to develop community exposure limits for over 1200 chemicals to date.
The new TEEL methodology enables emergency planners to develop useful approximations to peer-reviewed community exposure limits (such as the ERPGs) with a high degree of confidence. For definitions and acronyms, see Appendix.


L6 ANSWER 5 OF 17 MEDLINE
ACCESSION NUMBER: 2000050243 MEDLINE
DOCUMENT NUMBER: 20050243 PubMed ID: 10583160
TITLE: Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors.
AUTHOR: **Powell T J**; Ben-Bassat H; Klein B Y; Chen H; Shenoy N; McCollough J; Narog B; Gazit A; Harzstark Z; Chaouat M; Levitzki R; Tang C; McMahon J; Shawver L; Levitzki A
CORPORATE SOURCE: SUGEN, Inc; Redwood City, CA 94063, USA.
SOURCE: BRITISH JOURNAL OF DERMATOLOGY, **(1999 Nov)** 141 (5) 802-10.
Journal code: 0004041. ISSN: 0007-0963.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English

FILE SEGMENT: Priority Journals
ENTRY MONTH: 200005
ENTRY DATE: Entered STN: 20000512
Last Updated on STN: 20000512
Entered Medline: 20000502

AB Psoriasis is characterized by hyperproliferation of keratinocytes associated with an inflammatory infiltrate in the epidermis. Among factors which may be related to hyperplasia of psoriatic keratinocytes is the persistent autocrine stimulation of the epidermal growth factor receptor (EGFR) by transforming growth factor-alpha. Owing to the pivotal role of the EGFR in driving the growth of human psoriatic keratinocytes, we examined two selective inhibitors of EGFR kinase activity: 4-(3-bromophenylamino)-6, 7-dimethoxyquinazoline (AG1517/SU5271) and 4-(3-chlorophenylamino)-6, 7-dimethoxyquinazoline (AG1478) on psoriatic keratinocytes. SU5271 potently inhibits ligand-induced autophosphorylation of EGFR, and downstream signal transduction events, including DNA replication and cell cycle progression. SU5271, at micromolar concentrations, inhibited the proliferation of keratinocytes isolated from psoriatic lesions in excellent correlation with its EGFR kinase inhibitory activity in these cells. Biologically active concentrations of SU5271 penetrated human cadaver skin, suggesting that this compound is a strong candidate as an antipsoriatic agent.

L6 ANSWER 6 OF 17 MEDLINE
ACCESSION NUMBER: 1999440218 MEDLINE
DOCUMENT NUMBER: 99440218 PubMed ID: 10510523
TITLE: Recommended default methodology for analysis of airborne exposures to mixtures of chemicals in emergencies.
AUTHOR: Craig D K; Baskett R L; Davis J S; Dukes L; Hansen D J; Petrocchi A J; **Powell T J**; Sutherland P J; Tuccinardi T E Jr
CORPORATE SOURCE: Westinghouse Safety Management Solutions LLC, Aiken, South Carolina, USA.
SOURCE: APPLIED OCCUPATIONAL AND ENVIRONMENTAL HYGIENE, **(1999 Sep)** 14 (9) 609-17. Ref: 11
Journal code: 9103256. ISSN: 1047-322X.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199910
ENTRY DATE: Entered STN: 20000111
Last Updated on STN: 20000111
Entered Medline: 19991022

AB Emergency planning and hazard assessment of Department of Energy (DOE) facilities require consideration of potential exposures to mixtures of chemicals released to the atmosphere. Exposure to chemical mixtures may lead to additive, synergistic, or antagonistic health effects. In the past, the consequences of exposures to each chemical have been analyzed separately. This approach may not adequately protect the health of persons exposed to mixtures. This article presents default recommendations for use in emergency management and safety analysis within the DOE complex where

potential exists for releases of mixtures of chemicals. These recommendations were developed by the DOE Subcommittee on Consequence Assessment and Protective Actions (SCAPA). It is recommended that hazard indices (e.g., HIi = Ci/Limiti, where Ci is the concentration of chemical "i") be calculated for each chemical, and unless sufficient toxicological knowledge is available to indicate otherwise, that they be summed, that is, sigma i(n) = 1HIi = HI1 + HI2 + ... + HIn. A sum of 1.0 or less means the limits have not been exceeded. To facilitate application of these recommendations for analysis of exposures to specific mixtures, chemicals are classified according to their toxic consequences. This is done using health code numbers describing toxic effects by target organ for each chemical. This methodology has been applied to several potential releases of chemicals to compare the resulting hazard indices of a chemical mixture with those obtained when each chemical is treated independently. The methodology used and results obtained from analysis of one mixture are presented in this article. This article also demonstrates how health code numbers can be used to sum hazard indices only for those chemicals that have the same toxic consequence.

L6 ANSWER 7 OF 17 MEDLINE
ACCESSION NUMBER: 1999372831 MEDLINE
DOCUMENT NUMBER: 99372831 PubMed ID: 10445659
TITLE: Attitudes of AA contact persons toward group participation by persons with a mental illness.
AUTHOR: Meissen G; **Powell T J**; Wituk S A; Girrens K; Arteaga S
CORPORATE SOURCE: Department of Psychology, Wichita State University, Kansas 67260, USA.. meissen@twsu.edu
SOURCE: PSYCHIATRIC SERVICES, **(1999 Aug)** 50 (8) 1079-81. Journal code: 9502838. ISSN: 1075-2730.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199909
ENTRY DATE: Entered STN: 19990925
Last Updated on STN: 19990925
Entered Medline: 19990910
AB Alcoholics Anonymous groups are underused by persons with the dual diagnoses of mental illness and substance use disorder, and mental health professionals are cautious about referring them to AA because of fears that the AA group will discourage them from taking prescribed medication. The study assessed the attitudes of 125 AA contact persons about the participation of persons with mental illness. The majority had positive attitudes toward such persons, and 93 percent indicated that they should continue taking their medication. Fifty-four percent felt that participation in a group especially for persons with a dual diagnosis would be more desirable than in a traditional AA group. However, such groups are often not available.

L6 ANSWER 8 OF 17 MEDLINE
ACCESSION NUMBER: 1999111045 MEDLINE
DOCUMENT NUMBER: 99111045 PubMed ID: 9815796
TITLE: Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
AUTHOR: Shawver L K; Schwartz D P; Mann E; Chen H; Tsai J; Chu L; Taylorson L; Longhi M; Meredith S; Germain L; Jacobs J S;

Tang C; Ullrich A; Berens M E; Hersh E; McMahon G; Hirth K P; **Powell T J**
CORPORATE SOURCE: SUGEN, Inc., Redwood City, California 94063, USA.
SOURCE: CLINICAL CANCER RESEARCH, **(1997 Jul)** 3 (7) 1167-77.
Journal code: 9502500. ISSN: 1078-0432.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199902
ENTRY DATE: Entered STN: 19990311
Last Updated on STN: 20000303
Entered Medline: 19990225

AB Many reports have cited coexpression of platelet-derived growth factor (PDGF) and its receptors by tumor cells or cells supporting tumor growth, suggesting both autocrine and paracrine mechanisms for PDGF-mediated tumor growth. We found that a small organic molecule, N-[4-(trifluoromethyl)phenyl] 5-methylisoxazole-4-carboxamide (SU101, leflunomide), inhibited PDGF-mediated signaling events, including receptor tyrosine phosphorylation, DNA synthesis, cell cycle progression, and cell proliferation. SU101 inhibited PDGF-stimulated tyrosine phosphorylation of PDGF receptor (PDGFR) beta in C6 (rat glioma) and NIH3T3 cells engineered to overexpress human PDGFRbeta (3T3-PDGFRbeta). SU101 blocked both PDGF- and epidermal growth factor (EGF)-stimulated DNA synthesis. Previously, this compound was shown to inhibit pyrimidine biosynthesis by interfering with the enzymatic activity of dihydroorotate dehydrogenase. In the current study, EGF-stimulated DNA synthesis was restored by the addition of saturating quantities of uridine, whereas PDGF-induced DNA synthesis was not, suggesting that the compound demonstrated some selectivity for the PDGFR pathway that was independent of pyrimidine biosynthesis. Selectivity was further demonstrated by the ability of the compound to block the entry of PDGF-stimulated cells into the S phase of the cell cycle, without affecting cell cycle progression of EGF-stimulated cells. In cell growth assays, SU101 selectively inhibited the growth of PDGFRbeta-expressing cell lines more efficiently than it inhibited the growth of PDGFRbeta-negative cell lines. SU101 inhibited the s.c., i.p., and intracerebral growth of a panel of cell lines including cells from glioma, ovarian, and prostate origin. In contrast, SU101 failed to inhibit the in vitro or s.c. growth of A431 and KB tumor cells, both of which express EGF receptor but not PDGFRbeta. SU101 also inhibited the growth of D1B and L1210 (murine leukemia) cells in syngeneic immunocompetent mice, without causing adverse effects on the immune response of the animals. In an i.p. model of tumor growth in syngeneic immunocompetent mice, SU101 prevented tumor growth and induced long-term survivors in animals implanted with 7TD1 (murine B-cell hybridoma) tumor cells. Because PDGFRbeta was detected on most of the tumor cell lines in which in vivo growth was inhibited by SU101, these data suggest that SU101 is an effective inhibitor of PDGF-driven tumor growth in vivo.

L6 ANSWER 9 OF 17 MEDLINE
ACCESSION NUMBER: 1999107211 MEDLINE
DOCUMENT NUMBER: 99107211 PubMed ID: 9892193
TITLE: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that

inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

AUTHOR: Fong T A; Shawver L K; Sun L; Tang C; App H; **Powell T J**; Kim Y H; Schreck R; Wang X; Risau W; Ullrich A; Hirth K P; McMahon G

CORPORATE SOURCE: SUGEN, Inc., South San Francisco, California 94080, USA.. fong@progenitor.com

SOURCE: CANCER RESEARCH, **(1999 Jan 1)** 59 (1) 99-106.
Journal code: 2984705R. ISSN: 0008-5472.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199902

ENTRY DATE: Entered STN: 19990216
Last Updated on STN: 20000303
Entered Medline: 19990204

AB SU5416, a novel synthetic compound, is a potent and selective inhibitor of the Flk-1/KDR receptor tyrosine kinase that is presently under evaluation in Phase I clinical studies for the treatment of human cancers. SU5416 was shown to inhibit vascular endothelial growth factor-dependent mitogenesis of human endothelial cells without inhibiting the growth of a variety of tumor cells in vitro. In contrast, systemic administration of SU5416 at nontoxic doses in mice resulted in inhibition of subcutaneous tumor growth of cells derived from various tissue origins. The antitumor effect of SU5416 was accompanied by the appearance of pale white tumors that were resected from drug-treated animals, supporting the antiangiogenic property of this agent. These findings support that pharmacological inhibition of the enzymatic activity of the vascular endothelial growth factor receptor represents a novel strategy for limiting the growth of a wide variety of tumor types.

L6 ANSWER 10 OF 17 MEDLINE

ACCESSION NUMBER: 96317074 MEDLINE

DOCUMENT NUMBER: 96317074 PubMed ID: 8743300

TITLE: A follow-up study of patients hospitalized after minor head injury.

AUTHOR: **Powell T J**; Collin C; Sutton K

CORPORATE SOURCE: Psychology Department, Erleigh Road Clinic, Reading, UK.

SOURCE: DISABILITY AND REHABILITATION, **(1996 May)** 18 (5) 231-7.
Journal code: 9207179. ISSN: 0963-8288.

PUB. COUNTRY: ENGLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199610

ENTRY DATE: Entered STN: 19961025
Last Updated on STN: 20000303
Entered Medline: 19961016

AB Minor head injury accounts for 95% of all head injury. In this study 62 patients, hospitalized after minor head injury, were assessed within 48 h, and invited to attend for review and retesting 3 months later. Thirty-five

patients were followed up in this way and 11 more were interviewed over the telephone. There was significant improvement on all psychometric tests between initial evaluation and follow-up. Between 51% and 86% reported troublesome late post-concussional symptoms, of which headaches and tiredness were the most frequently reported symptoms. Length of post-traumatic amnesia (PTA) was related to severity of symptoms. Clinical levels of anxiety and stress were noted in approximately one-third of the whole group; 95% of the group had returned to work by 3 months with a mean absence rate of 9.4 days. The therapeutic implications of these results are discussed.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 5.90 | 40.99 |

STN INTERNATIONAL LOGOFF AT 11:54:22 ON 18 MAR 2003